ArticleClinical interventions in aging2025
Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute myocardial infarction (AMI) in the elderly is associated with high morbidity and mortality, with major adverse cardiovascular events (MACE) remaining a major concern despite early revascularization. This study aimed to evaluate the association of soluble suppression of tumorigenicity 2 (sST2), interleukin-33 (IL-33), and homocysteine (Hcy) with coronary stenosis severity and their predictive value for MACE in elderly AMI patients. Methods: A retrospective analysis was conducted on 143 elderly AMI patients (≥65 years) admitted between June 2022 and June 2024. Patients were divided into two groups based on MACE occurrence: Group A (no MACE, n=56) and Group B (MACE, n=87). Serum sST2, IL-33, and Hcy levels were measured using ELISA, and coronary stenosis severity was assessed using the Gensini score. Statistical analyses included Spearman correlation, multivariate logistic regression, and receiver operating characteristic (ROC) curve analysis to evaluate predictive performance. Results: Serum sST2, IL-33, and Hcy levels were significantly higher in the MACE group compared to the non-MACE group (72.37±10.68 vs 38.76±11.15, p<0.05; 60.61±10.89 vs 33.74±11.23, p<0.05; 32.76±4.15 vs 15.38±4.62, p<0.05, respectively). Biomarker levels positively correlated with coronary stenosis severity (sST2: r=0.647, p<0.05; IL-33: r=0.659, p<0.05; Hcy: r=0.582, p<0.05). Multivariate logistic regression confirmed that sST2 (OR=1.056, 95% CI: 1.015-1.094, p=0.005), IL-33 (OR=1.069, 95% CI: 1.024-2.016, p=0.001), and Hcy (OR=1.037, 95% CI: 1.008-1.077, p=0.033) were independent risk factors for MACE. ROC analysis showed that sST2, IL-33, and Hcy had AUCs of 0.841 (95% CI: 0.762-0.915, p<0.001), 0.803 (95% CI: 0.724-0.878, p<0.001), and 0.729 (95% CI: 0.642-0.812, p<0.001), respectively. Combined detection of all three biomarkers significantly improved MACE prediction (AUC=0.910, 95% CI: 0.851-0.956, p<0.001). Conclusion: Serum sST2, IL-33, and Hcy levels are positively correlated with coronary stenosis severity and independently associated with MACE in elderly AMI patients. Their combined detection significantly enhances MACE prediction, providing a potential strategy for improved risk stratification and management in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.